Sernova Biotherapeutics Inc (TSX: SVA)
Health Care · Biotechnology · CA
CA$0.11
0.00% today · -38.9% 1Y
Sernova Biotherapeutics Inc (TSX: SVA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $30.17M and employs 8 people.
Over the last twelve months the share price has lost 38.9%, trading between 0.10 and 0.20.
Tweenvest scores Sernova Biotherapeutics Inc across four factors: quality 6/100. Its strongest factor is quality.
SVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $30.17M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 0.64
- 52-week high
- CA$0.20
- 52-week low
- CA$0.10
- Avg volume (3M)
- —
- Shares outstanding
- 377.64M
- Employees
- 8
- Next earnings
- —
About Sernova Biotherapeutics Inc
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
- ISIN
- CA81752F1062
- Listed since
- Apr 29, 1999
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.